Literature DB >> 2195006

Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.

J H Greist1, J W Jefferson, R Rosenfeld, L D Gutzmann, J S March, N E Barklage.   

Abstract

Thirty-two nondepressed patients with obsessive compulsive disorder were randomly assigned to treatment with clomipramine (N = 16) or placebo (N = 16) in a 10-week double-blind study. Of the 15 patients who received at least 3 weeks of clomipramine treatment, 11 (73%) improved, 5 (33%) improved by more than 50%, and none worsened. Only 2 (12.5%) of the 16 placebo-treated patients improved, 1 (6%) by more than 50%; two (13%) worsened. Clomipramine treatment was associated with statistically significant improvement on several measures of obsessive compulsive symptoms. Side effects were more frequent and severe with clomipramine than with placebo. Although most patients tolerated clomipramine well, 3 discontinued treatment because of side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195006

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

2.  Placebo: a potent but misunderstood psychotrope.

Authors:  Y D Lapierre
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

Review 3.  Obsessive-compulsive disorder in children and adolescents. A review of the literature.

Authors:  Per Hove Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1994-07       Impact factor: 4.785

4.  Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder.

Authors:  A Fernández-Guasti; R E Ulloa; H Nicolini
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

Review 5.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

6.  Obsessive Compulsive and Related Disorders: From the Biological Basis to a Rational Pharmacological Treatment.

Authors:  Gabriele Sachs; Andreas Erfurth
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

Review 7.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 8.  Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time.

Authors:  Georgios D Kotzalidis; Antonio Del Casale; Maurizio Simmaco; Lucia Pancheri; Roberto Brugnoli; Marco Paolini; Ida Gualtieri; Stefano Ferracuti; Valeria Savoja; Ilaria Cuomo; Lavinia De Chiara; Alessio Mosca; Gabriele Sani; Paolo Girardi; Maurizio Pompili; Chiara Rapinesi
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.